Sun Pharmaceutical Industries has announced the U.S. launch of Cequa for treatment of dry eye.
The topical cyclosporine ophthalmic solution 0.09% is delivered via nanomicellar technology, which is intended to result in improved tissue penetration. The product launch follows the publication of a phase 3 study that showed a statistically significant improvement in Schirmer’s score among dry eye patients treated with Cequa.
“The U.S. launch of Cequa, the third product in our growing ophthalmic portfolio, marks the availability of a truly innovative treatment option for patients with dry eye disease — an area with a high unmet medical need,” Abhay Gandhi, CEO of Sun Pharma North America, said in a press release. “As a higher concentration cyclosporine product than what is currently commercially available, delivered with NCELL technology, Cequa continues to demonstrate our leadership in creating novel formulations of proven medications.”